stockportfolio.pro
Stocks / ARQT vs RLAY
ARQT vs RLAY
Arcutis Biotherapeutics, Inc. and Relay Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Arcutis Biotherapeutics, Inc. (ARQT) | Relay Therapeutics, Inc. (RLAY) | |
|---|---|---|
| Market cap | $3.0B | $3.1B |
| Revenue (latest FY) | $376.07M | $15.36M |
| Net income (latest FY) | $-16.14M | $-276.48M |
| Revenue growth (5y CAGR) | — | -28.6% |
| Net margin | -4.3% | -1800.6% |
| Return on equity | -8.5% | -48.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ARQT — free Open RLAY — freeFrequently asked questions
Which is bigger, ARQT or RLAY?
Relay Therapeutics, Inc. is larger by market capitalization — $3.1B versus $3.0B.
Which grows faster, ARQT or RLAY?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.